Marcus Messmer is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 44 publications with 2,381 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
Sponsor: Fox Chase Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202520 payments$15,350openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
- BeOne Medicines USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44.8%Kinase inhibitor35.6%Brukinsa74%Calquence26%Part D<11 patientsMethyltransferase Inhibitor4.8%Tazverik100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
20.2%Corticosteroid11.2%Prednisone100%Part D≥11 patientsSerotonin-3 Receptor Antagonist9%Ondansetron Hcl100%Part D≥16 patientsNervous system
16%Atypical Antipsychotic8.1%Olanzapine100%Part D≥11 patientsOther antidepressants4.2%Mirtazapine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Elizabeth Plimack, MD
Fox Chase Cancer Center
Martin Edelman, MD
Fox Chase Cancer Center
Shazia Nakhoda, MD
Fox Chase Cancer Center
Hossein Borghaei, MD
Fox Chase Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”